We’re very pleased to announce that OVIVA has now reached its recruitment target. It’s an extraordinary achievement for all concerned. To our knowledge, OVIVA is one of, or the largest ever prospective trials comparing oral and IV antibiotics in adults and stands to inform treatment choices for bone and joint infection worldwide. With confirmation from the TSC and the study Sponsor, we are now closed to recruitment.
Despite this being an open label trial, none of the research team in Oxford have any idea of the results to date, so the next essential objective is to ensure complete and timely data capture; without this, the work we’ve all invested so far could be jeopardised. We are therefore at the crucial stage of continuing to collect all study data within the time frame stipulated in the protocol.